Skip to main content
SpringerLink
Log in

Building a global culture of trial registration

  • Chapter
Clinical Trial Registries

  • 579 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Office of the New York State Attorney General Eliot Spitzer. Major pharmaceutical firm concealed information. Available at http://www.oag.state.ny.us/press/2004/jun/jun2b_04.html (Accessed 17 March 2005)

    Google Scholar 

  2. Krleža-Jerić K (2005) Clinical trial registration: the differing views of industry, the WHO, and the Ottawa Group. PLoS Med 2: e378.

    Article  PubMed  Google Scholar 

  3. Goodyear M (2006) Learning from the TGN 1412 trial. Br Med J 332: 677–678

    Article  Google Scholar 

  4. Abbasi K (2004) Compulsory registration of clinical trials. Br Med J 329: 637–638

    Article  Google Scholar 

  5. DeAngelis CD, Drazen JM, Frizelle FA et al (2004) Clinical trial registration: a statement from the International Committee on Medical Journal Editors. JAMA 292: 1363–1364

    Article  PubMed  CAS  Google Scholar 

  6. Krleža-Jerić K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C (2005) Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). Br Med J 330: 956–958

    Article  Google Scholar 

  7. Dong BJ, Young R, Rapaport B (1986) The nonequivalence of thyroid products. Drug Intell Clin Pharmacol 20: 77–78

    CAS  Google Scholar 

  8. Eckert CH (1997) Bioequivalence of levothyroxine preparations: industry sponsorship and academic freedom. JAMA 277: 1200–1201

    Article  PubMed  CAS  Google Scholar 

  9. Rennie D (1997) Thyroid storm. JAMA 277: 1238–1243

    Article  PubMed  CAS  Google Scholar 

  10. Spigelman MK (1997) Bioequivalence of levothyroxine preparations for treatment of hypothyroidism. JAMA 277: 1199–1200

    Article  PubMed  CAS  Google Scholar 

  11. Hippocratic Oath. Available at http://www.hal-pc.org/~ollie/hippocratic.oath.html (Accessed 16 April 2006)

    Google Scholar 

  12. Declaration of Geneva. http://www.donoharm.org.uk/gendecl.html (Accessed 17 April 2006)

    Google Scholar 

  13. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at http://www.wma.net/e/policy/pdf.17c.pdf (Accessed 31 March 2006)

    Google Scholar 

  14. CIHR Web site. Available at http://www.cihr-irsc.gc.ca (Accessed 31 March 2006)

    Google Scholar 

  15. Chan A-W, Krleža-Jerić K, Schmid I, Altman DG (2004) Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 171: 735–740

    PubMed  Google Scholar 

  16. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in clinical trials. JAMA 291: 2457–2365

    Article  PubMed  CAS  Google Scholar 

  17. Moher D, Bernstein A (2004) Registering CIHR-funded randomized controlled trials: a global public good. CMAJ 171: 750–775

    PubMed  Google Scholar 

  18. International Standard Randomised Clinical Trial Number. Available at http://isrctn.org (Accessed 15 April 2006)

    Google Scholar 

  19. Derbis J, Toigo T, Woods J, Evelyn B, Banks D (2003) FDAMA 113:Information program on clinical trials for serious or life threatening diseases: update on implementation. Ninth Annual FDA Science Forum; April 24, 2003, Washington, DC. Available at http://www.fda.gov/oashi/clinicaltrials/section113/biolaw.html (Accessed 30 March 2006)

    Google Scholar 

  20. Toigo T (2004) Food and Drug Modernization Act (FDAMA) Section 113: Status report on implementation. J Biolaw Bus 7. From: http://www.fda.gov (Accessed April 2006)

    Google Scholar 

  21. Fergusson D, Glass KC, Hutton B, Shapiro S (2005) Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding? Clin Trials 2: 218–229

    Article  PubMed  Google Scholar 

  22. Ottawa Group Web site. Available at http://ottawagroup.ohri.ca (Accessed 1 April 2006)

    Google Scholar 

  23. Krleža-Jerić K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C (2005) The Ottawa Statement, Part One: Principles for international registration of protocol information and results from human trials of health-related interventions. Jpn Pharmacol Ther 33: 544–548

    Google Scholar 

  24. Evans T, Gülmezoglu M, Pang T (2004) Registering clinical trials: an essential role for WHO. Lancet 363: 1413–1414

    Article  PubMed  Google Scholar 

  25. Gülmezoglu AM, Pang T, Horton R, Dickersin K (2005) WHO facilitates international collaboration in setting standards for clinical registration. Lancet 365: 1829–1831

    Article  PubMed  Google Scholar 

  26. World Health Organisation Web site. Available at http://www.who.int (Accessed 31 March 2006)

    Google Scholar 

  27. Abbasi K, Godlee F (2005) Next steps in trial registration; minimum criteria have been agreed, and intentions restated. Br Med J 330: 1222–1223

    Article  Google Scholar 

  28. De Angelis C, Drazen JM, Frizelle FA et al (2005) Is this clinical trial fully registered? — A statement from the International Committee of Medical Journal Editors. N Engl J Med 325: 2436–2438

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Randomised Controlled Trials Unit, Canadian Institutes of Health Research, Ottawa, Ontario, Canada

    Karmela Krleža-Jerić

Authors
  1. Karmela Krleža-Jerić
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abraxis BioScience, Inc., 11777 San Vincente Blvd Suite 550, Los Angeles, CA, 90049, USA

    MaryAnn Foote

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Krleža-Jerić, K. (2006). Building a global culture of trial registration. In: Foote, M. (eds) Clinical Trial Registries. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7583-6_5

Download citation

Publish with us

Policies and ethics

Search

Navigation